Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 946-245-5 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
No experimental toxico-kinetic data are available for assessing absorption, distribution, metabolisation and excretion of the substance. Based on effects seen in the human health toxicity studies and physico-chemical parameters the substance is expected to be readily absorbed via the oral and inhalation route and somewhat lower via the dermal route. Using the precautionary principle for route to route extrapolation the final absorption percentages derived are: 50% oral absorption, 50% dermal absorption and 100% inhalation absorption.
Key value for chemical safety assessment
- Bioaccumulation potential:
- low bioaccumulation potential
- Absorption rate - oral (%):
- 50
- Absorption rate - dermal (%):
- 50
- Absorption rate - inhalation (%):
- 100
Additional information
Koavone (81786-75-6) toxico-kinetic assessment
Introduction
Koavone is a branched alkyl chain with a ketone bond. The substance is a liquid with a molecular weight (MW) of 182 that does not preclude absorption. The test material is not likely to hydrolyse. The test material has a low volatility (vapour pressure at 25 ⁰C 100 Pa (< 500 Pa)).
Absorption
Oral: The results of an extended dietary repeated dose reproscreen study of circa 90 days shows that the substance is being absorbed by the gastro-intestinal tract following oral administration because effects on kidneys were seen. The relatively low molecular weight and the moderate octanol/water partition coefficient (Log Kow 4.44 and water solubility (42 mg/L) would favour absorption through the gut. According to Martinez and Amidon (2002) the optimal log Kow falls within a range of 2-7 for oral absorption. This shows that Koavone is likely to be absorbed orally for at least 50%.
Skin: The substance is a not a skin and eye irritant but is a weak skin sensitizer which indicates that skin absorption occurs. Also based on the physico-chemical characteristics of the substance, being a liquid, its molecular weight (182), log Kow (4.44) and water solubility (42 mg/L) indicate that (some) dermal absorption can occur. The optimal MW and log Kow for dermal absorption is < 100 and in the range of 1-4, respectively (ECHA guidance, 7.12, Table R.7.12-3). Koavone is somewhat outside this optimal range and therefore less than 50% skin absorption can be anticipated.
Lungs: Absorption via the lungs is also indicated based on these physico-chemical properties. Though the inhalation exposure route is thought to be minor, because of its low volatility (100 Pa), the octanol/water partition coefficient (4.44), indicates that inhalation absorption is possible. The blood/air (BA) partition coefficient is another partition coefficient indicating lung absorption. Buist et al. 2012 have developed BA model for humans using the most important and readily available parameters:
Log PBA = 6.96 – 1.04 Log (VP) – 0.533 (Log) Kow – 0.00495 MW.
For Koavone the B/A partition coefficient would result in:
Log P (BA) = 6.96 – (1.04 x 2) – (0.533 x 4.44) – (0.00495 x 182) = 1.61
This means that Koavone has only a slight tendency to partition from air into blood. When the substance is inhaled less than 100% will be absorbed.
Distribution
The moderate water solubility of the test substance would limit distribution in the body via the water channels. The log Kow would suggest that the substance would pass through the biological cell membrane. However, due to the expected metabolisation the substance as such would limitedly accumulate in the body fat. This can be seen in the predicted BCF of 407 of the EpiSuite model being 407, which takes into account metabolisation.
Metabolism
The metabolisation of Koavone is predicted using OECD Toolbox 3 liver metabolism simulator. One of the metabolites is presented below as an example in which an OH group is attached to one of the methyl groups of the branched chain. Such an OH group may be attached to every branched methyl group (For the structures see the attached document in IUCLID Endpoint summary section 7.1). These metabolites are expected to be more water soluble, have lower Log Kow values and will therefore be more easily excreted. According to WHO (2000) information on metabolisation of secondary ketones it can be expected that the ketone will be reduced to an alcohol.
Excretion
Effects seen in the kidney of the rats indicate that one of the routes of excretion is through the urine. Any unabsorbed substance will be excreted via the faeces.
Discussion
The substance is expected to be readily absorbed, orally and via inhalation, based on the human toxicological information and physico-chemical parameters. Koavone is also expected to be absorbed dermally due to the observed skin sensitization. The MW and the log Kow are higher than the favourable range for dermal absorption but significant absorption is likely.
The IGHRC (2006) document of the HSE and mentioned in the ECHA guidance Chapter 8 will be followed to derive absorption values.
Oral to dermal extrapolation: There are adequate data via the oral route and the critical toxic effect is related to systemic effects and therefore route to route extrapolation is applicable. The toxicity of the substance will be due to the parent compound but also to its metabolites. The overriding principle will be to avoid situations where the extrapolation of data would underestimate toxicity resulting from human exposure to a chemical by the route to route extrapolation. Koavone is not expected to be detoxified in the gut because it is hydrolytically stable. Though some first pass effect via the liver may occur the toxicity via the dermal route will not be underestimated because absorption will be slower and the compound will also pass the liver. Therefore, it will be assumed that the oral absorption will equal dermal absorption. Using the asymmetric handling of uncertainty the oral absorption will be considered 50% (though likely to be higher) and the dermal absorption will be considered also 50% (though likely to be lower).
Oral to inhalation extrapolation: Though Koavone is not a volatile liquid some inhalation exposure will be calculated. Koavone is not a skin and eye irritant and the systemic effect will overrule the effects at the site of contact. In the absence of bioavailability data it is most precautionary that 100% of the inhaled vapour is bioavailable. For the oral absorption 50% has been used for route to route extrapolation to be precautionary for the dermal route. For inhalation absorption 100% will be used for route to route extrapolation, because this will be precautionary for the inhalation route.
Conclusion
Koavone is expected to be readily absorbed via the oral and inhalation route and somewhat lower via the dermal route based on toxicity and physico-chemical data. Using the precautionary principle for route to route extrapolation the final absorption percentages derived are: 50% oral absorption, 50% dermal absorption and 100% inhalation absorption.
References
Buist, H.E., Wit-Bos de, L., Bouwman, T., Vaes, W.H.J., 2012, Predicting blood:air partition coefficient using basic physico-chemical properties, Regul. Toxicol. Pharmacol., 62, 23-28.
IGHRC, 2006, Guidelines on route to route extrapolation of toxicity data when assessing health risks of chemicals,http://ieh.cranfield.ac.uk/ighrc/cr12[1].pdf
Martinez, M.N., And Amidon, G.L., 2002, Mechanistic approach to understanding the factors affecting drug absorption: a review of fundament, J. Clinical Pharmacol., 42, 620-643.
WHO, 2000, Evaluation of certain food additives, Technical Report Series 891, page 53/54,http://whqlibdoc.who.int/trs/WHO_TRS_891.pdf
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.